Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their benefits remain limited to a subset of patients, underscoring the need for more reliable biomarkers and novel therapeutic strategies. The gut microbiome has emerged as a critical modulator of systemic immunity and a promising determinant of ICI response. Evidence links specific microbial features, taxa, and bioactive metabolites to enhanced antitumor immunity, whereas disruptions, such as antibiotic exposure, are associated with poorer outcomes. Advances in sequencing and multi-omics technologies have provided more profound insights into microbiome-immune crosstalk, though methodological heterogeneity continues to challenge reproducibility. Translational studies demonstrate that microbiome-based intervention, including fecal microbiota transplantation (FMT), biotics supplementation, and engineered microbial strains, can enhance ICI efficacy or mitigate immune-related toxicities. Despite encouraging early clinical signals, broader implementation requires methodological rigor, standardized protocols, and innovative trial designs that account for host and environmental factors. For clinicians, the most immediate strategies involve prudent antibiotic stewardship and patient enrollment in microbiome-focused clinical trials. Overall, the gut microbiome is a promising biomarker and a therapeutic target, representing a new frontier for personalizing immunotherapy and improving patient outcomes in oncology.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their benefits remain limited to a subset of patients, underscoring the need for more reliable biomarkers and novel therapeutic strategies. The gut microbiome has emerged as a critical modulator of systemic immunity and a promising determinant of ICI response. Evidence links specific microbial features, taxa, and bioactive metabolites to enhanced antitumor immunity, while disruptions such as antibiotic exposure are associated with poorer outcomes. Advanced in sequencing and multi-omics technologies have provided deeper insights into microbiome-immune crosstalk, though methodological heterogeneity continues to challenge reproducibility. Translational studies demonstrate that microbiome-based intervention, including fecal microbiota transplantation (FMT), biotics supplementation, and engineered microbial strains, can enhance ICI efficacy or mitigate immune-related toxicities. Despite encouraging early clinical signals, broader implementation requires methodological rigor, standardized protocols, and innovative trial designs that account for host and environmental factors. For clinicians, the most immediate strategies involve prudent antibiotic stewardship and patient enrollment in microbiome-focused clinical trials. Overall, the gut microbiome represents both a predictive biomarker and a therapeutic target, offering a new frontier to refine immunotherapy and improve patient outcomes in oncology.
Triple-negative breast cancer (TNBC) represents a biologically aggressive subtype with limited therapeutic targets; however, tumor-infiltrating lymphocytes (TILs) have emerged as the most robust immune biomarker with compelling prognostic and predictive significance. This comprehensive review synthesizes current evidence on TIL assessment methodology; the immunobiological landscape of TNBC, including regulatory T cell populations and PD-L1 correlations; gene expression underpinnings of the tumor immune microenvironment; and systematic evidence from meta-analyses and clinical trials. Meta-analytic estimates demonstrate that high TIL levels are associated with improved overall survival (HR 0.58, 95% CI 0.48–0.71) and disease-free survival (HR 0.66, 95% CI 0.57–0.76), with each 10% TIL increment conferring incremental benefit. High TILs predict superior pathologic complete response to neoadjuvant chemotherapy (OR 2.14, 95% CI 1.43–3.19), with lymphocyte-predominant breast cancer achieving pCR rates exceeding 80% with pembrolizumab-based chemoimmunotherapy. Future directions include prospective TIL-guided treatment trials, artificial intelligence-enabled standardization, and emerging adoptive TIL cellular therapies for metastatic disease.
UNSTRUCTURED This study evaluated the effect of an 8-week, brief-session online Mindfulness-Based Stress Reduction (MBSR) program on mitigating psychological distress and enhancing psychological resilience in cancer patients, with the intention of reducing stress-related physiological burden. A quasi-experimental study was conducted with cancer outpatients experiencing mild-to-severe psychological stress. Participants attended eight weekly online MBSR sessions (20–25 minutes each) focused on emotional regulation and focused attention mindfulness practice. Psychological distress was measured using the Distress Thermometer Scale (DTS), and changes in the awareness of mental state were also assessed pre- and post-intervention. A total of 42 patients were enrolled in the study. The MBSR intervention was associated with a significant reduction in overall psychological distress scores (median DTS pre-test: 4.43; post-test: 3.02; p<0.001). The proportion of patients experiencing moderate to severe distress decreased from 66.7% to 50%. This reduction in distress suggests a decrease in chronic stress exposure, which is relevant to immune regulation. Notable improvements were observed across key psychophysical indicators. Anxiety decreased significantly from 71.4% to 16.7%. Sadness/depression dropped from 54.8% to 5.8%. Stress-related physical symptoms showed significant reductions in sleep disturbances (from 52.3% to 9.5%) and fatigue (from 61.9% to 14.3%). Mental state awareness, worry regarding survival decreased from 33.3% to 9.5%. In summary, the use of MBSR serves as an evidence-based, behavioral prescription that aligns with the core principles of empowering patients to utilize their mind-body connection to reduce disease burden and maximize quality of life.